Clinical Trial Update: Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update concerns VNX001 for interstitial cystitis and bladder pain syndrome, focusing on safety, efficacy, and dosing frequency. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Pain Syndrome
• Interstitial Cystitis

Drugs mentioned

• VNX001

Snippet

Sponsor: Vaneltix Pharma, Inc. | Conditions: Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Status: RECRUITING